Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

  • ID: 3720463
  • Drug Pipelines
  • 434 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Apogenix GmbH
  • Boehringer Ingelheim GmbH
  • Cortice Biosciences, Inc.
  • ERC Belgium SA
  • Merck & Co., Inc.
  • MORE
Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016

Summary

‘Recurrent Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2016’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Recurrent Glioblastoma Multiforme (GBM)
- The report reviews pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Recurrent Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects
- The report assesses Recurrent Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Recurrent Glioblastoma Multiforme (GBM)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Recurrent Glioblastoma Multiforme (GBM)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Recurrent Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc.
  • Apogenix GmbH
  • Boehringer Ingelheim GmbH
  • Cortice Biosciences, Inc.
  • ERC Belgium SA
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Recurrent Glioblastoma Multiforme (GBM) Overview

Therapeutics Development

Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) – Overview

Pipeline Products for Recurrent Glioblastoma Multiforme (GBM) – Comparative Analysis

Recurrent Glioblastoma Multiforme (GBM) – Therapeutics under Development by Companies

Recurrent Glioblastoma Multiforme (GBM) – Therapeutics under Investigation by Universities/Institutes

Recurrent Glioblastoma Multiforme (GBM) – Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Recurrent Glioblastoma Multiforme (GBM) – Products under Development by Companies

Recurrent Glioblastoma Multiforme (GBM) – Products under Investigation by Universities/Institutes

Recurrent Glioblastoma Multiforme (GBM) – Companies Involved in Therapeutics Development

AbbVie Inc.

Agenus, Inc.

Amgen Inc.

AngioChem Inc.

Apogenix GmbH

AstraZeneca Plc

Axelar AB

BeiGene, Ltd.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Cantex Pharmaceuticals, Inc.

Cavion LLC

Celldex Therapeutics, Inc.

Coherus BioSciences, Inc.

Cortice Biosciences, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EnGeneIC Ltd

ERC Belgium SA

GenSpera, Inc.

Genzyme Corporation

GW Pharmaceuticals Plc

ImmunoCellular Therapeutics, Ltd.

Karyopharm Therapeutics, Inc.

Les Laboratoires Servier SAS

Medicenna Therapeutics, Inc.

Merck & Co., Inc.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Oryx GmbH & Co. KG

Pfizer Inc.

Stemline Therapeutics, Inc.

Threshold Pharmaceuticals, Inc.

Tocagen Inc.

TRACON Pharmaceuticals, Inc.

Vascular Biogenics Ltd.

Vaximm AG

Virttu Biologics Limited

Recurrent Glioblastoma Multiforme (GBM) – Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(GWP-42002 + GWP-42003) - Drug Profile

abemaciclib - Drug Profile

acalabrutinib - Drug Profile

afatinib dimaleate - Drug Profile

AMG-595 - Drug Profile

asinercept - Drug Profile

AU-101 - Drug Profile

AU-105 - Drug Profile

axitinib - Drug Profile

AXL-1717 - Drug Profile

AZD-7451 - Drug Profile

bevacizumab biosimilar - Drug Profile

BGB-290 - Drug Profile

bosutinib - Drug Profile

buparlisib hydrochloride - Drug Profile

capmatinib - Drug Profile

Cellular Immunotherapy for Recurrent Glioblastoma Multiforme - Drug Profile

Cellular Immunotherapy to Target Interleukein 13 Receptor Alpha-2 for Acute Myelocytic Leukemia and Glioblastoma Multiforme - Drug Profile

CX-02 - Drug Profile

dacomitinib - Drug Profile

dasatinib - Drug Profile

depatuxizumab mafodotin - Drug Profile

DNX-2401 - Drug Profile

ERC-1671 - Drug Profile

evofosfamide - Drug Profile

flucytosine ER + vocimagene amiretrorepvec - Drug Profile

G-200 - Drug Profile

galunisertib - Drug Profile

golvatinib + lenvatinib - Drug Profile

golvatinib tartrate - Drug Profile

HSV-1716 - Drug Profile

ICT-121 - Drug Profile

infigratinib - Drug Profile

lenvatinib mesylate - Drug Profile

lonafarnib - Drug Profile

MDNA-55 - Drug Profile

mibefradil dihydrochloride - Drug Profile

mipsagargin - Drug Profile

nabiximols - Drug Profile

napabucasin - Drug Profile

NEO-100 - Drug Profile

nilotinib - Drug Profile

nivolumab - Drug Profile

ofranergene obadenovec - Drug Profile

ONC-201 - Drug Profile

Oncolytic Virus for Oncology - Drug Profile

Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology - Drug Profile

Oncolytic Virus to Target IL-12 for Oncology - Drug Profile

OS-2966 - Drug Profile

p28 - Drug Profile

paclitaxel trevatide - Drug Profile

Parvoryx - Drug Profile

pazopanib hydrochloride - Drug Profile

pembrolizumab - Drug Profile

ramucirumab - Drug Profile

rilotumumab - Drug Profile

rindopepimut - Drug Profile

S-49076 - Drug Profile

selinexor - Drug Profile

SGT-53 - Drug Profile

SL-701 - Drug Profile

sonidegib phosphate - Drug Profile

TPI-287 - Drug Profile

TRC-102 - Drug Profile

trebananib - Drug Profile

vandetanib - Drug Profile

VEDVDox - Drug Profile

vorinostat - Drug Profile

VXM-01 - Drug Profile

Recurrent Glioblastoma Multiforme (GBM) – Recent Pipeline Updates

Recurrent Glioblastoma Multiforme (GBM) - Dormant Projects

Recurrent Glioblastoma Multiforme (GBM) – Discontinued Products

Recurrent Glioblastoma Multiforme (GBM) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2016

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by AbbVie Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Agenus, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Amgen Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by AngioChem Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Apogenix GmbH, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by AstraZeneca Plc, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Axelar AB, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by BeiGene, Ltd., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Boehringer Ingelheim GmbH, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Boston Biomedical, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Bristol-Myers Squibb Company, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Cantex Pharmaceuticals, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Cavion LLC, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Celldex Therapeutics, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Coherus BioSciences, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Cortice Biosciences, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Eisai Co., Ltd., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Eli Lilly and Company, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by EnGeneIC Ltd, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by ERC Belgium SA, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by GenSpera, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Genzyme Corporation, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by GW Pharmaceuticals Plc, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Les Laboratoires Servier SAS, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Medicenna Therapeutics, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Merck & Co., Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Novartis AG, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Oryx GmbH & Co. KG, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Pfizer Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Stemline Therapeutics, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Threshold Pharmaceuticals, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Tocagen Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by TRACON Pharmaceuticals, Inc., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Vascular Biogenics Ltd., H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Vaximm AG, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Pipeline by Virttu Biologics Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Recurrent Glioblastoma Multiforme (GBM) Therapeutics – Recent Pipeline Updates, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Dormant Projects, H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Dormant Projects (Contd..1), H1 2016

Recurrent Glioblastoma Multiforme (GBM) – Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM), H1 2016

Number of Products under Development for Recurrent Glioblastoma Multiforme (GBM) – Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AbbVie Inc.
Agenus, Inc.
Amgen Inc.
AngioChem Inc.
Apogenix GmbH
AstraZeneca Plc
Axelar AB
BeiGene, Ltd.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Cavion LLC
Celldex Therapeutics, Inc.
Coherus BioSciences, Inc.
Cortice Biosciences, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EnGeneIC Ltd
ERC Belgium SA
GenSpera, Inc.
Genzyme Corporation
GW Pharmaceuticals Plc
ImmunoCellular Therapeutics, Ltd.
Karyopharm Therapeutics, Inc.
Les Laboratoires Servier SAS
Medicenna Therapeutics, Inc.
Merck & Co., Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Oryx GmbH & Co. KG
Pfizer Inc.
Stemline Therapeutics, Inc.
Threshold Pharmaceuticals, Inc.
Tocagen Inc.
TRACON Pharmaceuticals, Inc.
Vascular Biogenics Ltd.
Vaximm AG
Virttu Biologics Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll